Search
Research
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockadeW. Joost Ben Lizeth Rachael Tao Omar Lesterhuis Wylie Orozco Morales Zemek Wang Elaskalani BSc PhD BSc, MSc, PhD BSc (Hons), PhD PhD BSc, MSc, PhD
News & Events
New study exposes link between pesticides and childhood brain tumoursA new Telethon Institute study has revealed a potential link between pesticide treatments in the home and a higher risk of children developing brain tumours.
News & Events
Exposure to diesel exhaust increases risk of child brain tumoursResearch at Telethon Institute has shown a correlation between brain tumours in young children and their parents' exposure to diesel exhaust fumes before birth.
News & Events
Researchers find new insight into genetics of aggressive cancerResearchers at Telethon Institute have found genetic differences in the rare and aggressive NUT-midline carcinoma, presenting new treatment opportunities.
News & Events
Telethon Adventurers fund new brain tumour research fellowshipThe Telethon Adventurers have announced a new research fellowship to investigate the genes involved in childhood brain tumours.
News & Events
Perth researchers decipher genetic pattern that predicts leukaemia relapseCancer researchers at Perth's The Kids for Child Health Research have discovered a genetic pattern that predicts the likelihood of relapse
Research
Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort studyInvasive fungal disease is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
Research
Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked DataCitation: Bailey HD. Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked Data. JAMA Netw Open. 2024;7(3):e243075 Keywords:
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
Research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AMLHematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft.